VRTX Jan 2025 210.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 02:35PM EDT
Loading interactive chart…
- Zacks
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $394.28, indicating a +0.2% shift from the previous trading day.
- Zacks
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
- Business Wire
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
BOSTON, April 18, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548).
© 2024 Yahoo. All rights reserved.